IMV is always on the lookout for smart, talented, fun professionals who want to be difference-makers. See a summary of our current openings below.
IMV Inc. is a clinical-stage immuno-oncology company dedicated to making immunotherapies more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases. IMV's proprietary drug development platform provides a patented delivery formulation that enables controlled and prolonged exposure of antigens to the immune system. Lead product candidate DPX-Survivac is currently being evaluated in several clinical trials in advanced ovarian cancer in combination with other innovative immunotherapy agents.
© 2018 IMV Inc. All rights reserved.
130 Eileen Stubbs Avenue, Suite 19 Dartmouth, Nova Scotia B3B 2C4
© 2018 IMV Inc. All rights reserved.